Alnylam Wins BIO s Helix Award; Some Past Winners Have Little to Show for It

Feb 16, 2006

Premium

The Biotechnology Industry Organization this week awarded Alnylam Pharmaceuticals the James D. Watson Helix award for corporate excellence in the emerging/mid-cap category.

The award, presented during BIO's annual CEO and Investor meeting in New York, honors leadership in scientific innovation, company growth, and corporate citizenship. It is presented by the Long Island Life Sciences Initiative, and is jointly sponsored by BIO, Stony Brook University, and The Center for Biotechnology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Nov

05

Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Main menu